Pharma: the challenges of sustainability, research and innovation

From a study presented by Licia Soncini, President of Nomoshighlighting best practices in Italy in the pharmaceutical field, it should be noted that 4.4% of net emissions belong tohealthcare. The study was presented at the event ‘Pandemic, pharmaceutical strategy and ecological transition: the challenges of the Union of health and the war in Ukraine’. The data comes from a study published by Health care without harm.

Soncini emphasized that although human health and the environment are closely linked, Italy there are only a few companies, about 9%, that are on the way to durability. This study opened the panel of the event in which the theme of review of pharmaceutical legislation fromEuropean Union which should have arrived by the end of the year, but has probably been postponed to 2023.

In the field of health, as in the field of energy, the EU is losing the challenge with its global competitors, China And United States. On the European stage, as he says Marcello Cattaniapresident of Farmindustria, Italy is the country that invests less in research and development.

The industry nowadays has to refer not only to Italian regulations, but also to European regulations and companies need a path that suits them.